Cancer Letters
Volume 228, Issue 1 , Pages 91-96, 18 October 2005

Protein chip array profiling analysis of sera from neuroblastoma patients

Centre Léon Bérard, Unité d'Oncologie Moléculaire, 28 rue Laënnec 69008 LYON France, Université Claude Bernard Lyon I, 8 avenue Rockefeller 69008, Lyon, France

Received 26 November 2004; accepted 2 December 2004.

Abstract 

Neuroblastoma, the most common extracranial solid tumour in children, is characterised by highly heterogeneous clinical behaviour; patients are stratified into risk categories according to a combination of clinical and biological markers. However, identifying non-invasive prognostic markers predicting outcome independently from current risk-stratification features remains critical for better disease monitoring. Using the SELDI-TOF-MS technology (surface-enhanced laser desorption/ionization time-of-flight mass spectrometry), we found a serum biomarker that strongly correlates with prognosis in neuroblastoma patients. Subsequent peptide mapping identified this biomarker as SAA protein. In support of this observation, high SAA levels were detected by ELISA in the sera of patients with poor prognosis neuroblastoma. Based on this finding, promises and limitations of the approach are discussed.

Keywords: Neuroblastoma, SELDI-TOF-MS, SAA, Serum, ProteinChip arrays

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0304-3835(05)00321-6

doi:10.1016/j.canlet.2004.12.053

Cancer Letters
Volume 228, Issue 1 , Pages 91-96, 18 October 2005

Article Tools

* Image Usage & Resolution